AU2001218841A1 - Glycerophosphoinositol derivatives as modulators of cytosolic a2 phospholipase - Google Patents
Glycerophosphoinositol derivatives as modulators of cytosolic a2 phospholipaseInfo
- Publication number
- AU2001218841A1 AU2001218841A1 AU2001218841A AU1884101A AU2001218841A1 AU 2001218841 A1 AU2001218841 A1 AU 2001218841A1 AU 2001218841 A AU2001218841 A AU 2001218841A AU 1884101 A AU1884101 A AU 1884101A AU 2001218841 A1 AU2001218841 A1 AU 2001218841A1
- Authority
- AU
- Australia
- Prior art keywords
- modulators
- derivatives
- glycerophosphoinositol
- cytosolic
- phospholipase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000002326 glycerophosphoinositols Chemical class 0.000 title abstract 2
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 title 1
- 102000015439 Phospholipases Human genes 0.000 title 1
- 108010064785 Phospholipases Proteins 0.000 title 1
- 230000001086 cytosolic effect Effects 0.000 title 1
- 102100022893 Histone acetyltransferase KAT5 Human genes 0.000 abstract 1
- 108020002496 Lysophospholipase Proteins 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/117—Esters of phosphoric acids with cycloaliphatic alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/10—Phosphatides, e.g. lecithin
- C07F9/106—Adducts, complexes, salts of phosphatides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/16—Esters of thiophosphoric acids or thiophosphorous acids
- C07F9/165—Esters of thiophosphoric acids
- C07F9/177—Esters of thiophosphoric acids with cycloaliphatic alcohols
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Addiction (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Virology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IT2000/000447 WO2002038575A1 (fr) | 2000-11-07 | 2000-11-07 | Derives de glycerophosphoinositol utilises comme modulateurs de la phospholipase a2 cytosolique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2001218841A1 true AU2001218841A1 (en) | 2002-05-21 |
Family
ID=11133577
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001218841A Abandoned AU2001218841A1 (en) | 2000-11-07 | 2000-11-07 | Glycerophosphoinositol derivatives as modulators of cytosolic a2 phospholipase |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7625883B1 (fr) |
| EP (1) | EP1332149B1 (fr) |
| JP (1) | JP2004513176A (fr) |
| CN (1) | CN1300155C (fr) |
| AT (1) | ATE308548T1 (fr) |
| AU (1) | AU2001218841A1 (fr) |
| CA (1) | CA2427352C (fr) |
| DE (1) | DE60023758T2 (fr) |
| ES (1) | ES2252079T3 (fr) |
| IL (2) | IL155619A0 (fr) |
| WO (1) | WO2002038575A1 (fr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPS282602A0 (en) * | 2002-06-07 | 2002-06-27 | Garvan Institute Of Medical Research | Method of inhibiting cell proliferation |
| ES2439450T3 (es) * | 2004-07-09 | 2014-01-23 | Vascular Biogenics Ltd. | Proceso mejorado para la preparación de fosfolípidos oxidados |
| GB0510463D0 (en) * | 2005-05-23 | 2005-06-29 | Britania Pharmaceuticals Ltd | Improvements in or relating to organic materials |
| EP2382978A3 (fr) * | 2006-06-09 | 2012-01-18 | Erasmus University Medical Center Rotterdam | Modulation du système immunitaire par phospholipidiques d'inositol |
| WO2008090114A1 (fr) | 2007-01-24 | 2008-07-31 | Glaxo Group Limited | Compositions pharmaceutiques contenant du 2-méthoxy-5- (5-trifluorométhyl-tétrazol-i-yl-benzyl) - (2s-phényl-pipéridin-3s-yl-) |
| WO2009038533A1 (fr) * | 2007-09-17 | 2009-03-26 | Bioneris Ab | Procédé et moyens pour le traitement de la cachexie |
| JP5420848B2 (ja) * | 2008-02-28 | 2014-02-19 | 株式会社コーセー | 美白剤及び美白用皮膚外用剤 |
| JP2009269851A (ja) * | 2008-05-07 | 2009-11-19 | Nikko Chemical Co Ltd | プロスタグランジンｅ２産生抑制剤及びその利用 |
| WO2012158591A1 (fr) * | 2011-05-18 | 2012-11-22 | The Research Foundation Of State University Of New York | Produits et méthodes anti-blépharite |
| JP5670858B2 (ja) * | 2011-10-14 | 2015-02-18 | イ．エルレ．ビ．イスティトゥト ディ リチェルケ ビオテクノロジケ ソチエタ ペル アツィオニ | サイトゾルのホスホリパーゼのモジュレーターとしてのグリセロホスホイノシトール誘導体 |
| ITRM20120473A1 (it) * | 2012-10-04 | 2014-04-05 | Consiglio Nazionale Ricerche | Use of glycerophosphoinositols for the treatment of septic shock |
| JP5701371B2 (ja) * | 2012-12-28 | 2015-04-15 | 花王株式会社 | スフィンゴミエリン含有サプリメント |
| RU2580280C2 (ru) * | 2014-07-08 | 2016-04-10 | Общество с ограниченной ответственностью "НИТРОЗДРАВ" | Композиция для местного применения для снижения или снятия болевого синдрома |
| US20170304409A1 (en) * | 2014-09-24 | 2017-10-26 | ISTITUTO PROFILATTICO E FARMACEUTICO CANDIOLI & C. SPA in abbreviated form CANDIOLI FARMACEUTICI | Compositions useful for the prevention and/or treatment of infections and inflammations |
| CN104447856A (zh) * | 2014-12-11 | 2015-03-25 | 河南省农科院农副产品加工研究所 | 一种甘油磷脂酰肌醇的制备方法 |
| IT202200010199A1 (it) * | 2022-05-17 | 2023-11-17 | Plantarei Biotech S R L | Glicerofosfoinositolo nella prevenzione e nel trattamento di infezioni da covid-19 e metodo per il suo ottenimento |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2659048A1 (de) * | 1976-12-27 | 1978-07-06 | Nattermann A & Cie | Neue inositphosphatid-derivate und verfahren zur herstellung dieser verbindungen |
| FR2517310A1 (fr) * | 1981-11-27 | 1983-06-03 | Unilever Nv | Derives d'a-glycerophosphatidester, procede pour leur preparation, composition cosmetique ou pharmaceutique les contenant |
| US4585762A (en) * | 1982-07-30 | 1986-04-29 | Fujisawa Pharmaceutical Co., Ltd. | Phospholipid derivatives, processes for use thereof and pharmaceutical composition of the same |
| US4997761A (en) * | 1987-10-06 | 1991-03-05 | Houston Biotechnology Incorporated | Phosphatidyl treatment of viral disease |
| IT1239474B (it) * | 1989-10-27 | 1993-11-02 | Depha Team Srl | Composizioni farmaceutiche a base di l-alfa-glicerofosforil-d-myo- inositolo o suoi sali alcalini o alcalino-terrosi per la terapia delleneuropatie periferiche di origine dismetabolica o tossica, e delle cerebropatie su base organica e funzionale |
| IT1238683B (it) * | 1990-02-09 | 1993-09-01 | Istituto Chemioterapico | Procedimento di preparazione di l-a-glicerilfosforil-d-myoinositolo e suoi sali da fosfatidi grezzi o parzialmente purificati |
| IT1247093B (it) * | 1991-01-22 | 1994-12-12 | Flarer S R L Ora Castellini S | Derivati salini del gliceril fosforil mioinositolo ad attivita' terapeutica, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono |
| US5464754A (en) * | 1993-08-17 | 1995-11-07 | The Regents Of The University Of California | Assay and substrate for arachidonoyl-specific phospholipase A2 |
| US5478857A (en) * | 1993-12-23 | 1995-12-26 | Eli Lilly And Company | Use of PLA2 inhibitors as treatment for alzheimer's disease |
| DE19623950A1 (de) * | 1996-06-15 | 1997-12-18 | Boehringer Ingelheim Kg | Pharmazeutische Zubereitung in Form von Liposomen |
| US6801860B1 (en) * | 1999-02-15 | 2004-10-05 | Genetics Institute, Llc | Crystal structure of cPLA2 and methods of identifying agonists and antagonists using same |
| SE532388C2 (sv) * | 2008-03-14 | 2010-01-12 | Tetra Laval Holdings & Finance | Förpackningslaminat och -behållare med två separata gasbarriärskikt samt metod för deras framställning |
-
2000
- 2000-11-07 WO PCT/IT2000/000447 patent/WO2002038575A1/fr not_active Ceased
- 2000-11-07 IL IL15561900A patent/IL155619A0/xx unknown
- 2000-11-07 AU AU2001218841A patent/AU2001218841A1/en not_active Abandoned
- 2000-11-07 JP JP2002541107A patent/JP2004513176A/ja not_active Withdrawn
- 2000-11-07 ES ES00981612T patent/ES2252079T3/es not_active Expired - Lifetime
- 2000-11-07 US US10/415,881 patent/US7625883B1/en not_active Expired - Lifetime
- 2000-11-07 CA CA2427352A patent/CA2427352C/fr not_active Expired - Lifetime
- 2000-11-07 DE DE60023758T patent/DE60023758T2/de not_active Expired - Lifetime
- 2000-11-07 EP EP00981612A patent/EP1332149B1/fr not_active Expired - Lifetime
- 2000-11-07 AT AT00981612T patent/ATE308548T1/de not_active IP Right Cessation
- 2000-11-07 CN CNB008200076A patent/CN1300155C/zh not_active Expired - Lifetime
-
2003
- 2003-04-28 IL IL155619A patent/IL155619A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| EP1332149A1 (fr) | 2003-08-06 |
| CN1455779A (zh) | 2003-11-12 |
| EP1332149B1 (fr) | 2005-11-02 |
| ES2252079T3 (es) | 2006-05-16 |
| DE60023758D1 (en) | 2005-12-08 |
| WO2002038575A1 (fr) | 2002-05-16 |
| DE60023758T2 (de) | 2006-12-07 |
| ATE308548T1 (de) | 2005-11-15 |
| JP2004513176A (ja) | 2004-04-30 |
| IL155619A0 (en) | 2003-11-23 |
| CA2427352A1 (fr) | 2002-05-16 |
| US7625883B1 (en) | 2009-12-01 |
| IL155619A (en) | 2010-06-30 |
| CN1300155C (zh) | 2007-02-14 |
| CA2427352C (fr) | 2010-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2001218841A1 (en) | Glycerophosphoinositol derivatives as modulators of cytosolic a2 phospholipase | |
| EP1193270A3 (fr) | Pyrrolobenzodiazépines | |
| AP9901534A0 (en) | Pharmaceutical formulations. | |
| MXPA02009706A (es) | Metodo para sintesis de perindopril y sus sales farmaceuticamente aceptables. | |
| ES2114487B1 (es) | Mezcla estabilizante sinergistica. | |
| HN1995009160A (es) | Derivados de cicloalcano indol y azaindol | |
| CA2197496A1 (fr) | Composition comprenant une dispersion de particules de polymeres dans un milieu non aqueux | |
| DE69918122D1 (de) | Stabilisierung pharmazeutischer zusammensetzungen durch besonderen einsatz eines antioxidans | |
| AU2001296819A1 (en) | Nanoscale piezoelectric generation systems background of the invention | |
| DK0750631T3 (da) | Mercaptoacetylamido-1,3,4,5-tetrahydrobenzo[c]azepin-3-ondisulfidderivater som enkephalinase- og ACE-inhibitorer | |
| BR0011030A (pt) | Composições de cicloporina substancialmente livre de óleo | |
| BR9909819A (pt) | Amida, uso de amidas, e, preparação farmacêutica para uso oral, parenteral ou intraperitoneal | |
| BR9804027A (pt) | Novos beta-ceto ésteres | |
| BR9813817A (pt) | Análogos de hemiasterlina | |
| BG105539A (en) | Eletriptan hydrobromide monohydrate | |
| AU2881399A (en) | N1-modified glycopeptides | |
| USD444502S1 (en) | Holder for a writing instrument | |
| UY26574A1 (es) | " procedimiento para la separación enzimática de racematos de derivados de aminometil-aril-ciclohexanol". | |
| MXPA03008837A (es) | Una composicion farmaceutica estable de pravastatina. | |
| TR199701298T1 (xx) | Tetralinler. | |
| CA2388830A1 (fr) | Solution administree par voie orale contenant de la galanthamine et un edulcorant | |
| USD370417S (en) | Clock case | |
| USD391848S (en) | Front face of a carton | |
| ATE204286T1 (de) | Modifizierte alpha-d-glcp-(1,2)-alpha-d-glcp-(1, 3)-alpha-d-glcp-analoge | |
| EP1351680B8 (fr) | Utilisation de l'anethole-dithiolethione dans la prevention et le traitement de la tenotoxicite induite par un medicament |